LUCENTIS 10MG/ML VIAL 0.23 ML

Ranibizumab is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the "wet" type of age-related macular degeneration (AMD also ARMD) a common form of age-related vision loss. Ranibizumab is a monoclonal antibody that inhibits angiogenesis by inhibiting Vascular endothelial growth factor A a mechanism similar to Bevacizumab.